TransMedics Group (NASDAQ:TMDX – Free Report) had its price objective upped by UBS Group from $77.00 to $88.00 in a research report released on Monday morning,Benzinga reports. UBS Group currently has a neutral rating on the stock.
A number of other equities research analysts have also issued reports on the company. Wall Street Zen upgraded TransMedics Group from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Needham & Company LLC lifted their price objective on TransMedics Group from $106.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Barclays began coverage on TransMedics Group in a research note on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective on the stock. Finally, JPMorgan Chase & Co. upped their target price on TransMedics Group from $73.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, November 6th. Five investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $113.30.
Get Our Latest Research Report on TMDX
TransMedics Group Stock Up 1.2%
TransMedics Group stock opened at $92.01 on Monday. The company has a quick ratio of 4.15, a current ratio of 4.53 and a debt-to-equity ratio of 1.46. The business’s 50-day moving average price is $80.04 and its 200 day moving average price is $92.52. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of 24.93, a price-to-earnings-growth ratio of 1.70 and a beta of 2.14.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.21. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The firm had revenue of $203.01 million during the quarter, compared to analyst estimates of $178.06 million. During the same quarter in the previous year, the business earned $0.66 EPS. TransMedics Group’s revenue for the quarter was up 41.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that TransMedics Group will post 1.58 earnings per share for the current year.
Insider Buying and Selling at TransMedics Group
In other TransMedics Group news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was purchased at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the acquisition, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.90% of the company’s stock.
Hedge Funds Weigh In On TransMedics Group
Institutional investors and hedge funds have recently made changes to their positions in the stock. Pinnacle Wealth Planning Services Inc. lifted its position in shares of TransMedics Group by 24.9% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company’s stock worth $73,000 after purchasing an additional 174 shares during the last quarter. Plan A Wealth LLC increased its holdings in TransMedics Group by 3.9% in the third quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock valued at $448,000 after buying an additional 203 shares during the last quarter. IFP Advisors Inc raised its stake in TransMedics Group by 4.8% in the second quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock valued at $309,000 after buying an additional 213 shares in the last quarter. HB Wealth Management LLC raised its stake in TransMedics Group by 1.5% in the second quarter. HB Wealth Management LLC now owns 15,062 shares of the company’s stock valued at $1,000,000 after buying an additional 219 shares in the last quarter. Finally, Bessemer Group Inc. lifted its holdings in TransMedics Group by 0.5% during the 3rd quarter. Bessemer Group Inc. now owns 46,019 shares of the company’s stock worth $3,840,000 after buying an additional 220 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.
About TransMedics Group
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
Recommended Stories
- Five stocks we like better than TransMedics Group
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
